Impact of Brokerage Rating on Ocular Therapeutix, Inc.(OCUL)

Many Ocular Therapeutix, Inc.(OCUL) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Ocular Therapeutix Inc was Initiated by Cantor Fitzgerald on Feb 10, 2017 to Overweight, Price Target of the shares are set at $35.

Company has reported several Insider transactions to the SEC, on Dec 16, 2016, Amarpreet Sawhney (CEO) purchased 45,300 shares at 7.85 per share price.On Sep 17, 2015, James Fortune (Chief Operating Officer) sold 9,470 shares at 17.16 per share price.On Jun 15, 2015, Charles M Warden (director 10% owner) sold 320,000 shares at 22.00 per share price.

Ocular Therapeutix Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.11. Analyst had a consensus of $-0.50.Analysts expectations of $ .47.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.38 by 4 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating.

Ocular Therapeutix, Inc. (NASDAQ:OCUL): The stock price is expected to reach $ 32.25 in the short term. The number of analysts agreeing with this consensus is 4. The higher estimate for the short term price target is at $60 while the lower estimate is at $16. The standard deviation of the price stands at $19.67.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) rose 0.78% or 0.07 points on Tuesday and made its way into the gainers of the day. After trading began at $9.05 the stock was seen hitting $9.368 as a peak level and $8.83 as the lowest level. The stock ended up at $9.05. The daily volume was measured at 1,459,490 shares. The 52-week high of the share price is $14.5 and the 52-week low is $4.04. The company has a market cap of $228 million.

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.


For any feedback and suggestions contact author at

Add Comment